Toggle menu

MAPP2 Study

Start date:
June 2018
End date:
December 2019
Co-ordinated by:
Rachel O'Brien
Main trial site:
Royal Infimary Edinburgh

The development of a new point of care test will detect miR-122 and allow point of care diagnosis of paracetamol toxicity with the aim of improved patient stratification on presentation to hospital and, therefore, improve patient care.

The aim of the study is to establish a biobank of human serum samples from patients with paracetamol overdose to develop and test the performance of our point of care test. This is a prospective, observational cohort study of participants aged 16 years or over presenting to the ED/AMU aiming to recruit 326 participants.

Chief Investigator

Dr James Dear

Consultant in Acute Medicine & Toxicology

Research Team

Rachel O'Brien

Lead Research Nurse

Caroline Blackstock

AMU Senior Research Nurse

Claire Cheyne

Senior Research Nurse

More EMERGE Trials

Assisting in identifying patients with Humeral shaft fractures in the ED by screening.

Giving patient information sheets to introduce the study, so patient has had adequate time to read and make decision about going into the trial before going to the fracture clinic.

Read more

HU-FIX Trial

Identification and characterization of the clinical toxicology of novel psychoactive substances (NPS) by laboratory analysis of biological samples from recreational drug users.

Read more

IONA Study

Identification of Novel Psychoactive Substances (IONA)

To determine the association between high-sensitivity cardiac troponin concentration and obstructive coronary artery disease in patients presenting to the Emergency Department with suspected acute coronary syndrome and cardiac troponin concentration within the normal reference range using CTCA.

Read more

PRECISE-CTCA Trial

To determine the association between high-sensitivity cardiac troponin concentration and obstructive coronary artery disease in patients presenting to the Emergency Department with suspected acute coronary syndrome and cardiac troponin concentration within the normal reference range using CTCA.